drugset / Trial / NCT02406742
A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Safety, pharmacokinetics, and preliminary efficacy of CC-122 alone and in combination with ibrutinib and obinuzutumab. CC-122 has multiple activities, including immune modulation of several immune cell subsets and antiproliferative activity in CLL. CC-122 has also been shown to have a tolerable safety profile with some preliminary signs of efficacy with early human experience.
Timeline
- Start
- 2015-07-27
- Primary completion
- 2020-07-07
- Completion
- 2020-07-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Avadomide | Other / unclassified | — | — |
| Subject | Ibrutinib | Small molecule | — | — |
| Subject | Obinutuzumab | Monoclonal antibody | 1000 mg | Intravenous |